Table 2

Rare, non-synonymous/truncating or missense variants in WNK2 identified in additional international SPS cohorts

VariantExongnomADAllele numberNumber of homozygotesCADDPatientSPS criteriaOnset ageCRC index caseCohort
c.106_107insG (p.Pro36Argfs*121)1000N/ABN-1741,322NDE
c.1853G>A (p.Ser618Asn)800026.4RB-1157NNL
c.2758G>A (p.Ala920Thr)110.000131520/152 056015GCP2080011,327NAU
c.3418G>A (p.Gly1140Ser)1400023.9MUC-61,342NADE
c.3623C>T (p.Thr1208Met)150.0000065821/151 930026.6MUC-4*30NDE
c.5476C>T (p.Arg1826Trp)2300025.1BN-210355NDE
c.5656C>T (p.Arg1886Trp)230.002233219/152 194121.2RB-251NNL
BN-145329NADE
MUC-1116–01120NDE
c.5906C>G (p.Pro1969Arg)2400025.3GCP038001359NAU
c.6080C>G (p.Ala2027Gly)2500025.1BN-83318NADE
c.6512G>A (p.Ser2171Asn)2800023BN-1041,321NADE
  • A cut-off of 15 was used to selected possible pathogenic variants. SPS criteria: according to the 2010 WHO SPS clinical criteria.

  • *This patient did not fulfil SPS criteria but presented a large serrated polyp at 30 and strong CRC family history.

  • †This patient presented a serrated polyp count between 1 and 10.

  • AU, Australia; CADD, Combined Annotation Dependent Depletion Phred score; CRC, colorectal cancer; DE, Germany; gnomAD, Genome Aggregation Database variant frequency; N, no; NA, not available; NL, Netherlands; SPS, serrated polyposis syndrome; Y, yes.